RAGE 229

Pricing Availability   Qty
Cat.No. 7701 - RAGE 229 | C23H22N4O2 | CAS No. 2143072-85-7
Description: ctRAGE-DIAPH1 interaction antagonist; reduces inflammatory signaling in diabetic mice
Chemical Name: N-[4-[7-Cyano-4-(4-morpholinylmethyl)-2-quinolinyl]phenyl]acetamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (6)

Biological Activity for RAGE 229

RAGE 229 is an antagonist of the interaction between the cytoplasmic tail of the receptor for advanced glycation end products (ctRAGE) and the formin, Diaphanous-1 (DIAPH1) (KD for binding to ctRAGE = 2 nM). RAGE 229 inhibits the migration of human aortic smooth muscle cells in an in vitro wound healing assay (IC50 = 120 nM). RAGE 229 reduces short- and long-term complications of diabetes in mouse models, without lowering blood glucose concentrations. RAGE 229 also reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 and attenuates inflammatory signaling in diabetic mice.

Licensing Information

Sold under license from New York University

Technical Data for RAGE 229

M. Wt 386.45
Formula C23H22N4O2
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 2143072-85-7
PubChem ID 132020228
InChI Key VDYYVNHJRNDKDO-UHFFFAOYSA-N
Smiles N#CC=1C=CC=2C(=NC(=CC2CN3CCOCC3)C=4C=CC(=CC4)NC(=O)C)C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for RAGE 229

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 38.65 100

Preparing Stock Solutions for RAGE 229

The following data is based on the product molecular weight 386.45. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.59 mL 12.94 mL 25.88 mL
5 mM 0.52 mL 2.59 mL 5.18 mL
10 mM 0.26 mL 1.29 mL 2.59 mL
50 mM 0.05 mL 0.26 mL 0.52 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for RAGE 229

References are publications that support the biological activity of the product.

Manigrasso et al (2021) Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Sci.Transl.Med. 13 eabf7084 PMID: 34818060


If you know of a relevant reference for RAGE 229, please let us know.

View Related Products by Target

View Related Products by Product Action

View all RAGE Antagonists

Keywords: RAGE 229, RAGE 229 supplier, RAGE229, inhibitor, inhibits, interaction, receptor, for, advanced, glycation, end, products, RAGE, Diaphanous-1, DIAPH1, type, 1, 2, diabetes, anti-inflammatory, 7701, Tocris Bioscience

Citations for RAGE 229

Citations are publications that use Tocris products.

Currently there are no citations for RAGE 229. Do you know of a great paper that uses RAGE 229 from Tocris? Please let us know.

Reviews for RAGE 229

There are currently no reviews for this product. Be the first to review RAGE 229 and earn rewards!

Have you used RAGE 229?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration Product Guide

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Alzheimer's Poster

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Multiple Sclerosis Poster

Multiple Sclerosis Poster

Multiple sclerosis (MS) is an autoimmune disease that is characterized by focal demyelination and axon degeneration in the central nervous system. This poster summarizes the neurobiology and current therapies of MS.

Pain Poster

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.